Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients
详细信息 查看全文
- 作者：Collet Dandara ; Collen Mutowembwa Masimirembwa ; Ayoub Magimba ; Jane Sayi ; Sylvia Kaaya ; De K. Sommers ; J.R. Snyman and Julia Anne Hasler
- 刊名：European Journal of Clinical Pharmacology
- 出版年：2001
- 出版时间：April 2001
- 年：2001
- 卷：57
- 期：1
- 页码：11-17
- 全文大小：168 KB
- 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Pharmacology and Toxicology - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-1041
文摘
Objectives: The study was carried out to investigate the distribution of cytochrome P450 2D6 (CYP2D6) and CYP2C19 genotype frequencies in three African populations and to compare these frequencies between healthy individuals and psychiatric patients. Methods: Three hundred and eighty-four subjects from South Africa (Venda), Tanzania, and Zimbabwe who consented to the study were genotyped for CYP2D6 (CYP2D6*1, *2, *3, *4, *5, and *17) and CYP2C19 (CYP2C19*1, *2, and *3) by PCR-RFLP (polymerase chain reaction restriction fragment length polymorphism) techniques. Results: The genotypes for CYP2D6 predicted a poor metaboliser frequency of 2.3% (2/88) in Tanzanian psychiatric patients, 1.9% (2/106) in Tanzanian healthy controls and 2.6% (2/76) in the South African Venda. The low-activity CYP2D6*17 allele frequency was higher in psychiatric patients (30%, 53/176) than in healthy individuals (20%, 43/212) in Tanzanians. The frequencies for CYP2C19*2 genotypes were predictive of a low prevalence of poor metabolisers (PMs). The CYP2C19*3 allele was absent in the three populations studied. There was no difference in CYP2D6 or CYP2C19 PM genotype frequencies between psychiatric patients and healthy subjects. Conclusion: The genotype results predict a low prevalence of people with deficient CYP2D6 and CYP2C19 activity among linguistically (Bantu) related populations of East and Southern Africa. The high frequency of the low-activity CYP2D6*17 allele predicts that the Bantu people have a reduced capacity to metabolise drugs that are CYP2D6 substrates.